Receptor Tyrosine Kinase (RTKs) Mediated Potent Bioactive Ligand Targeted to Autoimmune Arthritis
Abstract
This review aims to explore the Pharmacological potential of some important bioactive targets linked to Receptor Tyrosine Kinase (RTK) receptors in autoimmune arthritic disorders. RTKs play a role in inflammation, immune cell activation, angiogenesis, cartilage degradation, and autoantibody formation. Focusing on these pathways will pave the way for establishing a new treatment option for diseases such as rheumatoid arthritis. In conditions like autoimmune arthritis, inflammation results from immune cells such as T cells, B cells, and macrophages becoming activated and infiltrating the joints. The signaling of several immune receptors, including the TNF and IL-1 receptors, which are considered as important mediators of inflammation, is mediated by RTKs. Herbal bioactives are considered safer than other systems of medicine and possess outstanding therapeutic potential. In this review, we have considered some crucial bioactives that interact with RTKs to modulate their signaling pathways to be helpful for the treatment of various autoimmune disorders like rheumatoid arthritis, etc.
Keywords: Receptor Tyrosine Kinase, herbal bioactive, therapeutic potential, autoimmune disorder, rheumatoid arthritis, inflammation
Keywords:
Receptor Tyrosine Kinase, herbal bioactive, therapeutic potential, autoimmune disorder, rheumatoid arthritis, inflammationDOI
https://doi.org/10.22270/jddt.v15i7.7284References
1. Li Z. Auto‐Immune Diseases Caused by Overactive Immune System. Topics in Health and Biomedical Engineering. 2018;1(1):6-8. https://doi.org/10.26480/wcmpr.01.2018.06.08
2. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain. 1995 Dec 1;63(3):289-302. https://doi.org/10.1016/0304-3959(95)00186-7
3. Ali S, Ali SA, Kondrapu P, Tripathi N, Kumar PB, Prasad PD, Tonape MM, Terse PP, Ameen MP M, Kumar S, Saha A. A brief review of pathophysiology and management of different types of arthritis.
4. Hasan AA, Khudhur HR, Hameed AK. Rheumatic autoimmune diseases (focus on RA): prevalence, types, causes and diagnosis. Karbala Journal of Pharmaceutical Sciences. 2022 Jan 1;1(20).
5. Costa DS. Prevalence, burden and healthcare needs of people living with Osteoarthritis in Portugal: contribution to the development of a Model of Care (Doctoral dissertation, Universidade NOVA de Lisboa (Portugal)).
6. Mrid RB, Bouchmaa N, Ainani H, El Fatimy R, Malka G, Mazini L. Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis. Biomedicine & Pharmacotherapy. 2022 Jul 1;151:113126. https://doi.org/10.1016/j.biopha.2022.113126
7. Varrassi G, Pergolizzi JV, Dowling P, Paladini A. Ibuprofen safety at the golden anniversary: are all NSAIDs the same? A narrative review. Advances in therapy. 2020 Jan;37(1):61-82. https://doi.org/10.1007/s12325-019-01144-9
8. Fouad YM, Yehia R. Hepato-cardiac disorders. World journal of hepatology. 2014 Jan 27;6(1):41. https://doi.org/10.4254/wjh.v6.i1.41
9. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunological reviews. 2005 Dec;208(1):207-27. https://doi.org/10.1111/j.0105-2896.2005.00334.x
10. Balogun TA, Ige OM, Alausa AO, Onyeani CO, Tiamiyu ZA, Omoboyowa DA, Saibu OA, Abdullateef OT. Receptor tyrosine kinases as a therapeutic target by natural compounds in cancer treatment. Future Journal of Pharmaceutical Sciences. 2021 Dec;7:1-5. https://doi.org/10.1186/s43094-021-00346-9
11. Shimizu M, Weinstein IB. Modulation of signal transduction by tea catechins and related phytochemicals. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2005 Dec 11;591(1-2):147-60. https://doi.org/10.1016/j.mrfmmm.2005.04.010
12. Liu X, Xiao X, Han X, Yao L, Lan W. A new therapeutic trend: natural medicine for ameliorating ischemic stroke via PI3K/Akt signaling pathway. Molecules. 2022 Nov 17;27(22):7963. https://doi.org/10.3390/molecules27227963
13. Gupta R, Panwar RB, Sharma A, Panwar SR, Rao RS, Gupta BK. Continuing burden of rheumatic heart disease in India. J Assoc Physicians India. 2020 Oct 1;68(10):60-5.
14. Palsra P, Raman Gupta DJ, Devi N, Dhiman S. RHEUMATOID ARTHRITIS: A REVIEW.
15. Uhlig T, Moe RH, Kvien TK. The burden of disease in rheumatoid arthritis. Pharmacoeconomics. 2014 Sep;32:841-51. https://doi.org/10.1007/s40273-014-0174-6
16. Aral SO, Holmes KK. The epidemiology of STIs and their social and behavioral determinants: industrialized and developing countries. Sexually Transmitted Diseases, 4th 3ed. New York: McGraw-Hill. 2008:53-92.
17. Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL. Sex and management of rheumatoid arthritis. Clinical reviews in allergy & immunology. 2019 Jun 15;56:333-45. https://doi.org/10.1007/s12016-018-8672-5
18. Elders MJ. The increasing impact of arthritis on public health. The Journal of Rheumatology. Supplement. 2000 Oct 1;60:6-8.
19. Shrivastava AK, Pandey A. Inflammation and rheumatoid arthritis. Journal of physiology and biochemistry. 2013 Jun;69:335-47. https://doi.org/10.1007/s13105-012-0216-5
20. Ainola M. Pannus invasion into cartilage and bone in rheumatoid arthritis.
21. ur Rehman S, Iqbal S, Shahid MU, Jahangir MS, Malik AL. Cartilage: structure, function, and the pathogenesis of osteoarthritis. InAdvancements in Synovial Joint Science-Structure, Function, and Beyond 2024 Jan 23. IntechOpen. https://doi.org/10.5772/intechopen.1003264
22. Buckwalter JA, Anderson DD, Brown TD, Tochigi Y, Martin JA. The roles of mechanical stresses in the pathogenesis of osteoarthritis: implications for treatment of joint injuries. Cartilage. 2013 Oct;4(4):286-94. https://doi.org/10.1177/1947603513495889
23. Cancedda R. Cartilage and bone extracellular matrix. Current pharmaceutical design. 2009 Apr 1;15(12):1334-48. https://doi.org/10.2174/138161209787846739
24. Li G, Yin J, Gao J, Cheng TS, Pavlos NJ, Zhang C, Zheng MH. Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes. Arthritis research & therapy. 2013 Dec;15:1-2. https://doi.org/10.1186/ar4405
25. Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: the cytokine connection. Cytokine. 2014 Dec 1;70(2):185-93. https://doi.org/10.1016/j.cyto.2014.06.019
26. Shrivastava AK, Pandey A. Inflammation and rheumatoid arthritis. Journal of physiology and biochemistry. 2013 Jun;69:335-47. https://doi.org/10.1007/s13105-012-0216-5
27. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best practice & research Clinical rheumatology. 2017 Feb 1;31(1):3-18. https://doi.org/10.1016/j.berh.2017.08.003
28. Wysocki T, Olesińska M, Paradowska-Gorycka A. Current understanding of an emerging role of HLA-DRB1 gene in rheumatoid arthritis-from research to clinical practice. Cells. 2020 May 2;9(5):1127. https://doi.org/10.3390/cells9051127
29. Hui LY. Localisation of Citrullinated and Carbamylated Proteins in the Inflamed Gingival Tissues of Rheumatoid Arthritis (Master's thesis, University of Malaya (Malaysia)).
30. Sokolova M. The Role of IgA Anti-Citrullinated Protein Antibodies (ACPA) in Rheumatoid Arthritis and Glycosylation Differences of IgA Subclasses. Friedrich-Alexander-Universitaet Erlangen-Nuernberg (Germany); 2023.
31. Shaikh PZ. Cytokines & their physiologic and pharmacologic functions in inflammation: A review. International Journal of Pharmacy & Life Sciences. 2011 Nov 1;2(11).
32. Sanchez-Lopez E, Coras R, Torres A, Lane NE, Guma M. Synovial inflammation in osteoarthritis progression. Nature Reviews Rheumatology. 2022 May;18(5):258-75. https://doi.org/10.1038/s41584-022-00749-9
33. Mukherjee A, Das B. The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritis. Biomaterials and Biosystems. 2024 Feb 21:100090. https://doi.org/10.1016/j.bbiosy.2024.100090
34. Spondyloarthropathies S, Arthropathies CI. Alterations in the Skeletal System: Metabolic and Rheumatoid Disorders.
35. Ciesielski O, Biesiekierska M, Panthu B, Soszyński M, Pirola L, Balcerczyk A. Citrullination in the pathology of inflammatory and autoimmune disorders: recent advances and future perspectives. Cellular and Molecular Life Sciences. 2022 Feb;79(2):94. https://doi.org/10.1007/s00018-022-04126-3
36. Kaur B, Singh P. Inflammation: Biochemistry, cellular targets, anti-inflammatory agents and challenges with special emphasis on cyclooxygenase-2. Bioorganic Chemistry. 2022 Apr 1;121:105663. https://doi.org/10.1016/j.bioorg.2022.105663
37. Silva LC, Ortigosa LC, Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010 Nov 1;2(6):817-33. https://doi.org/10.2217/imt.10.67
38. Kesharwani D, Paliwal R, Satapathy T, Paul SD. Rheumatiod arthritis: an updated overview of latest therapy and drug delivery. Journal of pharmacopuncture. 2019 Dec 31;22(4):210. https://doi.org/10.3831/KPI.2019.22.029
39. Roy K, Kanwar RK, Kanwar JR. Molecular targets in arthritis and recent trends in nanotherapy. International journal of nanomedicine. 2015 Aug 26:5407-20. https://doi.org/10.2147/IJN.S89156
40. Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics. 2017 Apr 7;7(6):1543. https://doi.org/10.7150/thno.15625
41. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochemical and biophysical research communications. 2004 Oct 15;323(2):630-5. https://doi.org/10.1016/j.bbrc.2004.08.145
42. Cawston TE, Young DA. Proteinases involved in matrix turnover during cartilage and bone breakdown. Cell and tissue research. 2010 Jan;339:221-35. https://doi.org/10.1007/s00441-009-0887-6
43. Ooka S, Kurokawa MS, Yokoyama M, Arito M, Sato T, Sato M, Takakuwa Y, Omoteyama K, Suematsu N, Kawahata K, Kato T. Effects of iguratimod on protein profiles of chondrosarcoma cells. Integr. Mol. Med.. 2017 Dec 14;4:1-8. https://doi.org/10.15761/IMM.1000315
44. Gerstenfeld LC, Einhorn TA. COX inhibitors and their effects on bone healing. Expert opinion on drug safety. 2004 Mar 1;3(2):131-6. https://doi.org/10.1517/14740338.3.2.131
45. Gizinski AM, Fox DA, Sarkar S. Co-stimulation and T cells as therapeutic targets. Best Practice & Research Clinical Rheumatology. 2010 Aug 1;24(4):463-77. https://doi.org/10.1016/j.berh.2009.12.015
46. Mrid RB, Bouchmaa N, Ainani H, El Fatimy R, Malka G, Mazini L. Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis. Biomedicine & Pharmacotherapy. 2022 Jul 1;151:113126. https://doi.org/10.1016/j.biopha.2022.113126
47. Drosos AA, Pelechas E, Voulgari PV. Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings. Rheumatology international. 2019 Aug 1;39(8):1331-41. https://doi.org/10.1007/s00296-019-04326-4
48. Sarkar PK, Hossain N, Nahid M, Alam J. Disease Modifying Anti-rheumatic Drugs (DMARDs). Bangladesh Journal of Child Health. 2018 Jul 31;42(2):79-85. https://doi.org/10.3329/bjch.v42i2.37763
49. Pawar AT, Baheti AM, Adate-More P, Upaganlawar A. Conventional Therapy for Rheumatoid Arthritis. Natural Products for the Management of Arthritic Disorders. 2020;26:2962-70. https://doi.org/10.2174/9789815050776122010004
50. Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, Ralandison S, Gasque P. Methotrexate an old drug with new tricks. International journal of molecular sciences. 2019 Oct 10;20(20):5023. https://doi.org/10.3390/ijms20205023
51. Choi J, Patel P, Fenando A. Sulfasalazine. InStatPearls [Internet] 2024 Mar 21. StatPearls Publishing. https://doi.org/10.1080/15424065.2024.2389325
52. Pasquini S, Contri C, Borea PA, Vincenzi F, Varani K. Adenosine and inflammation: here, there and everywhere. International journal of molecular sciences. 2021 Jul 19;22(14):7685. https://doi.org/10.3390/ijms22147685
53. Martinez GP, Zabaleta ME, Di Giulio C, Charris JE, Mijares MR. The role of chloroquine and hydroxychloroquine in immune regulation and diseases. Current pharmaceutical design. 2020 Oct 1;26(35):4467-85. https://doi.org/10.2174/1381612826666200707132920
54. Pawar AT, Baheti AM, Adate-More P, Upaganlawar A. Conventional Therapy for Rheumatoid Arthritis. Natural Products for the Management of Arthritic Disorders. 2020;26:2962-70. https://doi.org/10.2174/9789815050776122010004
55. Catrina AI. Studies of molecular mechanisms of action of TNF antagonists in rheumatoid arthritis. Karolinska Institutet; 2004 Nov 26.
56. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Mola EM, Pavelka K, Sany J, Settas L, Wajdula J. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. The Lancet. 2004 Feb 28;363(9410):675-81. https://doi.org/10.1016/S0140-6736(04)15640-7
57. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. The Lancet. 2013 Mar 16;381(9870):918-29. https://doi.org/10.1016/S0140-6736(12)61811-X
58. Pawar AT, Baheti AM, Adate-More P, Upaganlawar A. Conventional Therapy for Rheumatoid Arthritis. Natural Products for the Management of Arthritic Disorders. 2020;26:2962-70. https://doi.org/10.2174/9789815050776122010004
59. Vardanyan M, Parkin EC, Rodriguez Rilo HL. Infliximab/Anti‐TNF. Immunotherapy in Transplantation: Principles and Practice. 2010 Apr 16:385-98. https://doi.org/10.1002/9781444355628.ch26
60. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. Journal of pharmacy & pharmaceutical sciences. 2008 Sep 20;11(2):81s-110s. https://doi.org/10.18433/J3T886
61. Sakamoto C. Roles of COX-1 and COX-2 in gastrointestinal pathophysiology. Journal of gastroenterology. 1998 Sep;33:618-24. https://doi.org/10.1007/s005350050147
62. Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. Goodman and Gilman's the pharmacological basis of therapeutics. 2011;12:959-1004.
63. Sharma JN, Jawad NM. Adverse effects of COX‐2 inhibitors. The Scientific World Journal. 2005;5(1):629-45. https://doi.org/10.1100/tsw.2005.82
64. Mrid RB, Bouchmaa N, Ainani H, El Fatimy R, Malka G, Mazini L. Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis. Biomedicine & Pharmacotherapy. 2022 Jul 1;151:113126. https://doi.org/10.1016/j.biopha.2022.113126
65. Chikanza IC, Kozaci DL. Corticosteroid resistance in rheumatoid arthritis: molecular and cellular perspectives. Rheumatology. 2004 Nov 1;43(11):1337-45. https://doi.org/10.1093/rheumatology/keh333
66. Cadena DL, Gill GN. Receptor tyrosine kinases. The FASEB Journal. 1992 Mar;6(6):2332-7 https://doi.org/10.1096/fasebj.6.6.1312047
67. Roskoski Jr R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological research. 2014 Jan 1;79:34-74. https://doi.org/10.1016/j.phrs.2013.11.002
68. Stuttfeld E, Ballmer‐Hofer K. Structure and function of VEGF receptors. IUBMB life. 2009 Sep;61(9):915-22. https://doi.org/10.1002/iub.234
69. Grassot J, Gouy M, Perrière G, Mouchiroud G. Origin and molecular evolution of receptor tyrosine kinases with immunoglobulin-like domains. Molecular biology and evolution. 2006 Jun 1;23(6):1232-41. https://doi.org/10.1093/molbev/msk007
70. Ségaliny AI, Tellez-Gabriel M, Heymann MF, Heymann D. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. Journal of bone oncology. 2015 Mar 1;4(1):1-2. https://doi.org/10.1016/j.jbo.2015.01.001
71. Ségaliny AI, Tellez-Gabriel M, Heymann MF, Heymann D. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. Journal of bone oncology. 2015 Mar 1;4(1):1-2. https://doi.org/10.1016/j.jbo.2015.01.001
72. Tsygankov AY. Non-receptor protein tyrosine kinases. Front Biosci. 2003 May 1;8(6):S595-635. https://doi.org/10.2741/1106
73. Okada M. Regulation of the SRC family kinases by Csk. International journal of biological sciences. 2012 Nov 1;8(10):1385. https://doi.org/10.7150/ijbs.5141
74. Roskoski Jr R. Src protein-tyrosine kinase structure and regulation. Biochemical and biophysical research communications. 2004 Nov 26;324(4):1155-64. https://doi.org/10.1016/j.bbrc.2004.09.171
75. Yang WC, Ching KA, Tsoukas CD, Berg LJ. Tec kinase signaling in T cells is regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain. The Journal of Immunology. 2001 Jan 1;166(1):387-95. https://doi.org/10.4049/jimmunol.166.1.387
76. Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cellular signalling. 2010 Aug 1;22(8):1175-84. https://doi.org/10.1016/j.cellsig.2010.03.001
77. Shi S. Assessment of turmeric (Curcuma longa L.) varieties for yield and curcumin content (Master's thesis, Auburn University).
78. Mateen S, Zafar A, Moin S, Khan AQ, Zubair S. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clinica chimica acta. 2016 Apr 1;455:161-71. https://doi.org/10.1016/j.cca.2016.02.010
79. Balogh E. Downstream effects of targeting angiogenesis in the inflamed joint and systemic vasculature in inflammatory arthritis. PQDT-Global. 2019.
80. Shah M. Cutaneous scarring: Modulation by transforming growth factor-beta and its antagonists. The University of Manchester (United Kingdom); 1993.
81. Hung CY, Hsueh TY, Rethi L, Lu HT, Chuang AE. Advancements in regenerative medicine: a comprehensive review of stem cell and growth factor therapies for osteoarthritis. Journal of Materials Chemistry B. 2025. https://doi.org/10.1039/D4TB01769B
82. Bilski R, Nuszkiewicz J. Antioxidant Therapies as Emerging Adjuncts in Rheumatoid Arthritis: Targeting Oxidative Stress to Enhance Treatment Outcomes. International Journal of Molecular Sciences. 2025 Jan;26(7):2873. https://doi.org/10.3390/ijms26072873
83. Kumar A, Chopra K, Mukherjee M, Pottabathini R, Dhull DK. Current knowledge and pharmacological profile of berberine: an update. European journal of pharmacology. 2015 Aug 15;761:288-97. https://doi.org/10.1016/j.ejphar.2015.05.068
84. Sivasakthi P, Sanmuga Priya E, Senthamil Selvan PJ. Molecular insights into phytochemicals exhibiting anti-arthritic activity: Systematic review: John Di Battista. Inflammation Research. 2021 Jun;70(6):665-85. https://doi.org/10.1007/s00011-021-01471-0
85. Yang L, Wang NL, Cai GP. Maohuoside A promotes osteogenesis of rat mesenchymal stem cells via BMP and MAPK signaling pathways. Molecular and cellular biochemistry. 2011 Dec;358:37-44. https://doi.org/10.1007/s11010-011-0918-y
86. Wang X, Liu E, Hou C, Wang Y, Zhao Y, Guo J, Li M. Effects of natural products on angiogenesis in melanoma. Fitoterapia. 2024 Jul 6:106100. https://doi.org/10.1016/j.fitote.2024.106100
87. Szczuka D, Nowak A, Zakłos-Szyda M, Kochan E, Szymańska G, Motyl I, Blasiak J. American ginseng (Panax quinquefolium L.) as a source of bioactive phytochemicals with pro-health properties. Nutrients. 2019 May 9;11(5):1041. https://doi.org/10.3390/nu11051041
88. Jang WY, Hwang JY, Cho JY. Ginsenosides from Panax ginseng as key modulators of NF-κB signaling are powerful anti-inflammatory and anticancer agents. International Journal of Molecular Sciences. 2023 Mar 24;24(7):6119. https://doi.org/10.3390/ijms24076119
89. Ivanenkov YA, Balakin KV, Lavrovsky Y. Small molecule inhibitors of NF-kB and JAK/STAT signal transduction pathways as promising anti-inflammatory therapeutics. Mini Rev Med Chem. 2011 Jan 1;11(1):55-78. https://doi.org/10.2174/138955711793564079
90. Chen JY, Tian XY, Wei SS, Yang YJ, Deng S, Jiao CJ, Wang CJ, Chu KD, Ma XQ, Xu W. Perspectives of herbs and their natural compounds, and herb formulas on treating diverse diseases through regulating complicated JAK/STAT signaling. Frontiers in Pharmacology. 2022 Oct 17;13:993862. https://doi.org/10.3389/fphar.2022.993862
91. Sarkar J, Das M, Howlader MS, Prateeksha P, Barthels D, Das H. Epigallocatechin-3-gallate inhibits osteoclastic differentiation by modulating mitophagy and mitochondrial functions. Cell death & disease. 2022 Oct 28;13(10):908. https://doi.org/10.1038/s41419-022-05343-1
92. Riegsecker S, Wiczynski D, Kaplan MJ, Ahmed S. Potential benefits of green tea polyphenol EGCG in the prevention and treatment of vascular inflammation in rheumatoid arthritis. Life sciences. 2013 Sep 3;93(8):307-12. https://doi.org/10.1016/j.lfs.2013.07.006
93. Song C, Xu S, Chang L, Zhao X, Mei X, Ren X, Chen Z. Preparation of EGCG decorated, injectable extracellular vesicles for cartilage repair in rat arthritis. Regenerative biomaterials. 2021 Dec 1;8(6):rbab067. https://doi.org/10.1093/rb/rbab067
94. Malemud CJ. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clinica chimica acta. 2007 Jan 1;375(1-2):10-9. https://doi.org/10.1016/j.cca.2006.06.033
95. Wang X, Liu E, Hou C, Wang Y, Zhao Y, Guo J, Li M. Effects of natural products on angiogenesis in melanoma. Fitoterapia. 2024 Jul 6:106100. https://doi.org/10.1016/j.fitote.2024.106100
96. Kashyap VK, Peasah-Darkwah G, Dhasmana A, Jaggi M, Yallapu MM, Chauhan SC. Withaniasomnifera: progress towards a pharmaceutical agent for immunomodulation and cancer therapeutics. Pharmaceutics. 2022 Mar 10;14(3):611. https://doi.org/10.3390/pharmaceutics14030611
97. D'Aura Swanson C, Paniagua RT, Lindstrom TM, Robinson WH. Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nature Reviews Rheumatology. 2009 Jun;5(6):317-24. https://doi.org/10.1038/nrrheum.2009.82
98. Patidar V, Shah S, Kumar R, Singh PK, Singh SB, Khatri DK. A molecular insight of inflammatory cascades in rheumatoid arthritis and anti-arthritic potential of phytoconstituents. Molecular Biology Reports. 2022 Mar 1:1-7.
99. Shah AA, Gupta A. Phytochemicals and novel nanotherapeutic approaches in the management of rheumatic diseases. InInnovative Approaches for Nanobiotechnology in Healthcare Systems 2022 (pp. 249-266). IGI Global Scientific Publishing. https://doi.org/10.4018/978-1-7998-8251-0.ch009
100. Devikar SD, Naikawadi VB, Shirke HA, Aher RK, Nikam TD, Naikawadi VB. Regeneration through somatic embryogenesis from zygotic embryo explant of Boswellia serrata Roxb. and detection of medicinal boswellic acid.
101. Hongzhi D, Xiaoying H, Yujie G, Le C, Yuhuan M, Dahui L, Luqi H. Classic mechanisms and experimental models for the anti‐inflammatory effect of traditional Chinese medicine. Animal Models and Experimental Medicine. 2022 Apr;5(2):108-19. https://doi.org/10.1002/ame2.12224
102. Mioc M, Prodea A, Racoviceanu R, Mioc A, Ghiulai R, Milan A, Voicu M, Mardale G, Șoica C. Recent advances regarding the molecular mechanisms of triterpenic acids: A review (part II). International Journal of Molecular Sciences. 2022 Aug 10;23(16):8896. https://doi.org/10.3390/ijms23168896
103. Ammon HP. Boswellic acids and their role in chronic inflammatory diseases. Anti-inflammatory Nutraceuticals and Chronic Diseases. 2016:291-327. https://doi.org/10.1007/978-3-319-41334-1_13
104. Dixon RA, Ferreira D. Genistein. Phytochemistry. 2002 Jun 1;60(3):205-11. https://doi.org/10.1016/S0031-9422(02)00116-4
105. Peng Q, Li Y, Shang J, Huang H, Zhang Y, Ding Y, Liang Y, Xie Z, Chen C. Effects of genistein on common kidney diseases. Nutrients. 2022 Sep 13;14(18):3768. https://doi.org/10.3390/nu14183768
106. Sharifi-Rad J, Quispe C, Imran M, Rauf A, Nadeem M, Gondal TA, Ahmad B, Atif M, Mubarak MS, Sytar O, Zhilina OM. Genistein: an integrative overview of its mode of action, pharmacological properties, and health benefits. Oxidative medicine and cellular longevity. 2021;2021(1):3268136. https://doi.org/10.1155/2021/3268136
107. Goh YX, Jalil J, Lam KW, Husain K, Premakumar CM. Genistein: A review on its anti-inflammatory properties. Frontiers in pharmacology. 2022 Jan 24;13:820969. https://doi.org/10.3389/fphar.2022.820969
108. Sulaiman MK. Molecular mechanisms and therapeutic potential of natural flavonoids in diabetic nephropathy: Modulation of intracellular developmental signaling pathways. Current Research in Pharmacology and Drug Discovery. 2024 Jul 3:100194. https://doi.org/10.1016/j.crphar.2024.100194
109. Javed Z, Khan K, Herrera-Bravo J, Naeem S, Iqbal MJ, Sadia H, Qadri QR, Raza S, Irshad A, Akbar A, Reiner Ž. Genistein as a regulator of signaling pathways and microRNAs in different types of cancers. Cancer Cell International. 2021 Dec;21:1-2. https://doi.org/10.1186/s12935-021-02091-8
110. Frémont L. Biological effects of resveratrol. Life sciences. 2000 Jan 14;66(8):663-73. https://doi.org/10.1016/S0024-3205(99)00410-5
111. Ba X, Huang Y, Shen P, Huang Y, Wang H, Han L, Lin WJ, Yan HJ, Xu LJ, Qin K, Chen Z. WTD attenuating rheumatoid arthritis via suppressing angiogenesis and modulating the PI3K/AKT/mTOR/HIF-1α pathway. Frontiers in Pharmacology. 2021 Sep 27;12:696802. https://doi.org/10.3389/fphar.2021.696802
112. Yang G, Chang CC, Yang Y, Yuan L, Xu L, Ho CT, Li S. Resveratrol alleviates rheumatoid arthritis via reducing ROS and inflammation, inhibiting MAPK signaling pathways, and suppressing angiogenesis. Journal of agricultural and food chemistry. 2018 Dec 4;66(49):12953-60. https://doi.org/10.1021/acs.jafc.8b05047
113. Li Q, Chen Y, Liu H, Tian Y, Yin G, Xie Q. Targeting glycolytic pathway in fibroblast-like synoviocytes for rheumatoid arthritis therapy: challenges and opportunities. Inflammation Research. 2023 Dec;72(12):2155-67. https://doi.org/10.1007/s00011-023-01807-y
114. Byun JY, Koh YT, Jang SY, Witcher JW, Chan JR, Pustilnik A, Daniels MJ, Kim YH, Suh KH, Linnik MD, Lee YM. Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection. Scientific Reports. 2021 Sep 21;11(1):18671. https://doi.org/10.1038/s41598-021-98255-7
115. Tavakoli GM, Yazdanpanah N, Rezaei N. Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments. Advances in Rheumatology. 2024 Sep 30;64:61. https://doi.org/10.1186/s42358-024-00401-y
116. Dong XD, Lu Q, Li YD, Cai CY, Teng QX, Lei ZN, Wei ZH, Yin F, Zeng L, Chen ZS. RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells. Journal of Translational Internal Medicine. 2024 Jul 27;12(3):288-98.
117. Xu D, Kim Y, Postelnek J, Vu MD, Hu DQ, Liao C, Bradshaw M, Hsu J, Zhang J, Pashine A, Srinivasan D. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. The Journal of pharmacology and experimental therapeutics. 2012 Apr 1;341(1):90-103. https://doi.org/10.1124/jpet.111.187740
118. Xu D, Kim Y, Postelnek J, Vu MD, Hu DQ, Liao C, Bradshaw M, Hsu J, Zhang J, Pashine A, Srinivasan D. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. The Journal of pharmacology and experimental therapeutics. 2012 Apr 1;341(1):90-103. https://doi.org/10.1124/jpet.111.187740
119. D'Aura Swanson C, Paniagua RT, Lindstrom TM, Robinson WH. Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nature Reviews Rheumatology. 2009 Jun;5(6):317-24. https://doi.org/10.1038/nrrheum.2009.82
120. Baradaran Rahimi V, Askari VR, Hosseinzadeh H. Promising influences of Scutellaria baicalensis and its two active constituents, baicalin, and baicalein, against metabolic syndrome: A review. Phytotherapy research. 2021 Jul;35(7):3558-74. https://doi.org/10.1002/ptr.7046
121. Ye Z, Liu Y, Song J, Gao Y, Fang H, Hu Z, Zhang M, Liao W, Cui L, Liu Y. Expanding the therapeutic potential of Salvia miltiorrhiza: a review of its pharmacological applications in musculoskeletal diseases. Frontiers in Pharmacology. 2023 Dec 5;14:1276038. https://doi.org/10.3389/fphar.2023.1276038
122. Lee HE, Yang G, Han SH, Lee JH, An TJ, Jang JK, Lee JY. Anti-obesity potential of Glycyrrhiza uralensis and licochalcone A through induction of adipocyte browning. Biochemical and Biophysical Research Communications. 2018 Sep 10;503(3):2117-23. https://doi.org/10.1016/j.bbrc.2018.07.168
123. Ma J, Dey M, Yang H, Poulev A, Pouleva R, Dorn R, Lipsky PE, Kennelly EJ, Raskin I. Anti-inflammatory and immunosuppressive compounds from Tripterygium wilfordii. Phytochemistry. 2007 Apr 1;68(8):1172-8. https://doi.org/10.1016/j.phytochem.2007.02.021
124. Tong X, Wang Y, Dong B, Li Y, Lang S, Ma J, Ma X. Effects of genus Epimedium in the treatment of osteoarthritis and relevant signaling pathways. Chinese Medicine. 2023 Jul 31;18(1):92. https://doi.org/10.1186/s13020-023-00788-8
125. Chen P, Zhou J, Ruan AM, Ma YF, Wang QF. Paeoniflorin, the Main monomer component of paeonia lactiflora, exhibits anti-inflammatory properties in osteoarthritis synovial inflammation. Chinese Journal of Integrative Medicine. 2024 May;30(5):433-42. https://doi.org/10.1007/s11655-023-3653-9
126. Wu L, Yang Y, Mao Z, Wu J, Ren D, Zhu B, Qin L. Processing and compatibility of Corydalis yanhusuo: phytochemistry, pharmacology, pharmacokinetics, and safety. Evidence‐Based Complementary and Alternative Medicine. 2021;2021(1):1271953. https://doi.org/10.1155/2021/1271953
127. Ran X, Ma L, Peng C, Zhang H, Qin LP. Ligusticum chuanxiong Hort: a review of chemistry and pharmacology. Pharmaceutical Biology. 2011 Nov 1;49(11):1180-9. https://doi.org/10.3109/13880209.2011.576346
Published
Abstract Display: 524 
PDF Downloads: 392 PDF Downloads: 215 How to Cite
Issue
Section
Copyright (c) 2025 Nikita Patel , Trilochan Satapathy , Poonam Sahu , Pratibha Dhiwar , Kamaksha Tiwari , Laxmi Sahu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.